Skint, yes, I can agree with you. It would be nice to know who...

First 25 Last

Share
Profile

Follow
pivalde

1,078 Posts.

160

04/12/18

00:14

Post #: 36737071
Share

Originally posted by skint ↑

Originally posted by pivalde
This is now correct, in 1 year development has been poor and we are today on the same level as 2 y ago. During the previous year share price came from this 1.60 level up almost 100 %. But even 3.18 is very poor value if you compare what it was just before the results of Imagine study. So I do agree totally that market has lost much of its interest in this stock if you look at the share price. On the volume side evidence is not so clear ( volumes are low ) and volatility is very high.
The value of this stock is only in it's goal: to help neurodegeneration patient with the drugs it has developed. If it cannot help them there is no hope with Prana but if it can and does it better than other drug companies there is still a great future IMO. But this is only my opinion and it is not an advice to anybody to invest in Prana.
Hi pivalde, my take here is that this is just another fluctuation. They slowly walk the price down with no news, then drive it back up with or without news. Progress is painfully slow in this neurodegeneration drug space. Note nobody has developed an effective AD drug, and that includes pharma's with multi billion dollar R&D budgets. PSP drug development sent one small company I was following broke. Nobody has developed an effective ALS treatment. Animal models have not been very successful. The last successful HD drug development, led by Dr Stamler's team for Auspex (now Prana's Dr Stamler) was an adaptation of the previous approved HD drug. Prana's Ira Shoulson was instrumental in the approval of both drugs tetrabenazine and dutetetrabenazine. These guys are now in Prana's US based development team for PBT434. I fail to see how there could be no hope here. Auspex was acquired by the giant Teva for $3.2 billion in enterprise value and approximately $3.5 billion in equity value in 2015.
I think Prana could be more forthcoming on info from the screening of new compounds using the new 3D human neuron model they now have. I guess there will be news as patents are registered?
Note, as far as I can see Auspex had no approved drugs at the time of the acquisition and was founded in 2001. Dutetetrabenazine had completed phase3.
All just my opinion. DYOR

Expand

Skint, yes, I can agree with you. It would be nice to know who are those "walking the price down". But in any case I see hope in Prana more than 2 y ago as I already told here. But I would like Prana to tell us that PBT434 helps mitochondria to improve the energy supply of the nerve cells by eliminating accumulated iron hampering the function of mitochondria. The scientific paper demonstrating this was published only 1 month ago so perhaps we need to give some time to Prana ( Huang et al :
Iron-induced energy supply deficiency and mitochondrial fragmentation in neurons).

PBT Price at posting: 3.9¢ Sentiment: None Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

CAF

IP anomaly thrills Cannidah with project extension hopes in QLD

CMB

Asian Battery Metals uncover second massive sulphide discovery at Mongolia's Oval play

ASX Market Open: Aussie market to leap on best 'Trump trade' bump since election day | November 22, 2024

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

PCL

HotCopper users react as Pancontinental Energy's trading halt lift reveals little

ALY

Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

C1X

iTech inks deal with Chilean lithium giant to progress Reynolds Range

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

There are more pages in this discussion • 35 more messages in this thread...

First 25 Last

Add PBT (ASX) to my watchlist

Skint, yes, I can agree with you. It would be nice to know who...

Top Stories

IP anomaly thrills Cannidah with project extension hopes in QLD

Asian Battery Metals uncover second massive sulphide discovery at Mongolia's Oval play

ASX Market Open: Aussie market to leap on best 'Trump trade' bump since election day | November 22, 2024

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

HotCopper users react as Pancontinental Energy's trading halt lift reveals little

Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

iTech inks deal with Chilean lithium giant to progress Reynolds Range

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Featured News